He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid tumor of midgut origin with large segment 3 liver metastasis. Carcinoid syndrome and carcinoid heart disease. Management.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.